DMXL2

Across TCGA pan-cancer cohorts, DMXL2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DMXL2 data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher DMXL2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated DMXL2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

COAD, LUAD, and LSCC are the cancer types where DMXL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	0.916	1.000	.031	12	view →
LUAD	DFS	Median	All	0.646	0.923	.016	8	view →
LSCC	OS	Median	III,IV	0.868	0.441	.011	7	view →
CCRCC	OS	Median	II,III,IV	0.602	0.855	.011	7	view →
GBM	DFS	Quartile	All	0.901	0.629	.009	4	view →
PDAC	DFS	Median	III,IV	0.852	0.537	.025	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DMXL2–COAD (DFS)

Open the COAD breakdown →